Key result
Angiotensin II receptor blockers did not demonstrate superior efficacy compared to ACE inhibitors in acute coronary syndromes and may potentially increase cardiovascular risk.
Why the study?
Are angiotensin II receptor blockers (ARBs) as effective and safe as angiotensin-converting enzyme inhibitors (ACEIs) in the management of acute coronary syndromes?
Are angiotensin II receptor blockers (ARBs) as effective and safe as angiotensin-converting enzyme inhibitors (ACEIs) in the management of acute coronary syndromes?
Answers are grounded in this paper and cite their sources.
This review suggests caution when using ARBs as an alternative to ACEIs in acute coronary syndromes, as clinical evidence does not support their superior efficacy and raises potential safety concerns.
BACKGROUND: It is well known that inappropriate or exaggerated activity of the renin-angiotensin system might contribute to the development of systemic hypertension with consequent organ injury and associated increased risk of acute cardiovascular (CV) diseases. This review will discuss evidence form basic research and clinical studies, investigating the efficacy of angiotensin II receptor blockers (ARBs) in the management of acute coronary syndromes (ACS). MATERIALS AND METHODS: This narrative review is based on the material found on MEDLINE and PubMed up to June 2013. We looked for the terms 'angiotensin, AT1 receptor, ACE inhibitors' in combination with 'acute coronary syndromes, acute myocardial infarction, pathophysiology'. RESULTS: Preclinical studies showed relevant protective effects of ARBs to reduce adverse cardiac remodelling in animal models of acute cardiac ischaemia. However, although recommended in Consensus guidelines as a good alternative to angiotensin-converting enzyme inhibitors (ACEIs), clinical studies did not confirm a superior efficacy of the ARBs as compared to ACEIs. As a matter of fact for some authors, these drugs might potentially have deleterious effects increasing the CV risk. CONCLUSIONS: Emerging evidence from clinical trials suggests that the use of ARBs in ACS might be controversial, and caution should be used for their clinical use to replace ACEIs in ACS.
No takes yet. Share an insight, caveat, or question.
Artom et al. (2013) conducted a review in acute coronary syndromes. angiotensin II receptor blockers (ARBs) vs. angiotensin-converting enzyme inhibitors (ACEIs) was evaluated. Angiotensin II receptor blockers did not demonstrate superior efficacy compared to ACE inhibitors in acute coronary syndromes and may potentially increase cardiovascular risk.
Synapse has enriched 10 related papers. Consider them for comparative context: